Shares of Biogen, a US biotech company, trade around 50% higher in premarket today. Shares rally following results of an Alzheimer drug (Lecanemab) trial that Biogen developed along with Eisai, Japanese pharmaceutical company. Results showed that the pace of cognitive decline in patients who received Lecanemab dropped by 27% over 18 months compared to patients who received placebo. This is massive as it is the first drug to show effectiveness against Alzheimer in a definitive, large-scale trial. While the company noted that some side effects occurred, it also said that they were rarely severe.
Biogen trades around 50% higher in premarket today. Weekly chart. Source: xStation5
Oracle Paradox: ลงทุนหนัก แต่หนี้กลับพุ่งสูงขึ้น
Palantir Preview: ราคาหุ้นสะท้อนความสมบูรณ์แบบแล้วหรือยัง?
US500 ฟื้นตัวหลังการขายออก📈 วิเคราะห์ฤดูกาลประกาศผลกำไรของวอลล์สตรีท🗽
เหลือเวลาไม่กี่วัน รีบรับหุ้นฟรี ⏳
